Literature DB >> 22719003

Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease.

Yaping Chu1, Gerardo A Morfini, Lori B Langhamer, Yinzhen He, Scott T Brady, Jeffrey H Kordower.   

Abstract

The progressive loss of the nigrostriatal pathway is a distinguishing feature of Parkinson's disease. As terminal field loss seems to precede cell body loss, we tested whether alterations of axonal transport motor proteins would be early features in Parkinson's disease. There was a decline in axonal transport motor proteins in sporadic Parkinson's disease that preceded other well-known nigral cell-related pathology such as phenotypic downregulation of dopamine. Reductions in conventional kinesin levels precede the alterations in dopaminergic phenotypic markers (tyrosine hydroxylase) in the early stages of Parkinson's disease. This reduction was significantly greater in nigral neurons containing α-synuclein inclusions. Unlike conventional kinesin, reductions in the levels of the cytoplasmic dynein light chain Tctex type 3 subunit were only observed at late Parkinson's disease stages. Reductions in levels of conventional kinesin and cytoplasmic dynein subunits were recapitulated in a rat genetic Parkinson's disease model based on over-expression of human mutant α-synuclein (A30P). Together, our data suggest that α-synuclein aggregation is a key feature associated with reductions of axonal transport motor proteins in Parkinson's disease and support the hypothesis that dopaminergic neurodegeneration following a 'dying-back' pattern involving axonal transport disruption.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22719003      PMCID: PMC4571141          DOI: 10.1093/brain/aws133

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  37 in total

1.  Single-molecule observations of neck linker conformational changes in the kinesin motor protein.

Authors:  Michio Tomishige; Nico Stuurman; Ronald D Vale
Journal:  Nat Struct Mol Biol       Date:  2006-10-01       Impact factor: 15.369

2.  Nurr1 in Parkinson's disease and related disorders.

Authors:  Yaping Chu; Weidong Le; Katie Kompoliti; Joseph Jankovic; Elliott J Mufson; Jeffrey H Kordower
Journal:  J Comp Neurol       Date:  2006-01-20       Impact factor: 3.215

3.  A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers.

Authors:  Jillian Madine; Andrew J Doig; David A Middleton
Journal:  Biochemistry       Date:  2006-05-09       Impact factor: 3.162

4.  Molecular motors implicated in the axonal transport of tau and alpha-synuclein.

Authors:  Michelle A Utton; Wendy J Noble; Josephine E Hill; Brian H Anderton; Diane P Hanger
Journal:  J Cell Sci       Date:  2005-09-21       Impact factor: 5.285

5.  Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

Authors:  Yaping Chu; Jeffrey H Kordower
Journal:  Neurobiol Dis       Date:  2006-10-18       Impact factor: 5.996

Review 6.  Alpha-synuclein and presynaptic function: implications for Parkinson's disease.

Authors:  Simon Lykkebo; Poul Henning Jensen
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

7.  Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability.

Authors:  Nicholas M Kanaan; Jeffrey H Kordower; Timothy J Collier
Journal:  J Comp Neurol       Date:  2007-06-10       Impact factor: 3.215

8.  Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice.

Authors:  Sylvia E Perez; Orly Lazarov; James B Koprich; Er-Yun Chen; Virginia Rodriguez-Menendez; Jack W Lipton; Sangram S Sisodia; Elliott J Mufson
Journal:  J Neurosci       Date:  2005-11-02       Impact factor: 6.167

Review 9.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

10.  Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number.

Authors:  Steven W Flavell; Christopher W Cowan; Tae-Kyung Kim; Paul L Greer; Yingxi Lin; Suzanne Paradis; Eric C Griffith; Linda S Hu; Chinfei Chen; Michael E Greenberg
Journal:  Science       Date:  2006-02-17       Impact factor: 47.728

View more
  107 in total

1.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

2.  Phosphorylation at serine 31 targets tyrosine hydroxylase to vesicles for transport along microtubules.

Authors:  Ana Jorge-Finnigan; Rune Kleppe; Kunwar Jung-Kc; Ming Ying; Michael Marie; Ivan Rios-Mondragon; Michael F Salvatore; Jaakko Saraste; Aurora Martinez
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

3.  Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A2A receptor over-activation in a rat model of Parkinson's disease.

Authors:  Marta Carmo; Francisco Q Gonçalves; Paula M Canas; Jean-Pierre Oses; Francisco D Fernandes; Filipe V Duarte; Carlos M Palmeira; Angelo R Tomé; Paula Agostinho; Geanne M Andrade; Rodrigo A Cunha
Journal:  Br J Pharmacol       Date:  2019-08-01       Impact factor: 8.739

Review 4.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

5.  Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.

Authors:  Laura L Dugan; LinLin Tian; Kevin L Quick; Josh I Hardt; Morvarid Karimi; Chris Brown; Susan Loftin; Hugh Flores; Stephen M Moerlein; John Polich; Samer D Tabbal; Jonathan W Mink; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2014-07-22       Impact factor: 10.422

Review 6.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

7.  Do subjects with minimal motor features have prodromal Parkinson disease?

Authors:  Yaping Chu; Aron S Buchman; C Warren Olanow; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2018-03-10       Impact factor: 10.422

8.  Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons.

Authors:  Hélène Doucet-Beaupré; Catherine Gilbert; Marcos Schaan Profes; Audrey Chabrat; Consiglia Pacelli; Nicolas Giguère; Véronique Rioux; Julien Charest; Qiaolin Deng; Ariadna Laguna; Johan Ericson; Thomas Perlmann; Siew-Lan Ang; Francesca Cicchetti; Martin Parent; Louis-Eric Trudeau; Martin Lévesque
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-12       Impact factor: 11.205

Review 9.  Microtubule Destabilization Paves the Way to Parkinson's Disease.

Authors:  D Cartelli; G Cappelletti
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

10.  Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.

Authors:  Adam L Orr; Florentine U Rutaganira; Daniel de Roulet; Eric J Huang; Nicholas T Hertz; Kevan M Shokat; Ken Nakamura
Journal:  Neurochem Int       Date:  2017-04-20       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.